Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Healthy Participants

Interventions: Drug: BMS-986165
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2018-05-30

Last Posted Date: 2020-01-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT03541564

Locations: 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Completed

Conditions: Venous Thromboembolism (VTE)

First Posted Date: 2018-05-11

Last Posted Date: 2022-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35756

Registration Number: NCT03521908

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase 2

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Biological: Nivolumab
Biological: BCG
Drug: BMS-986205

First Posted Date: 2018-05-08

Last Posted Date: 2023-06-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 142

Registration Number: NCT03519256

Locations: 🇺🇸
Local Institution - 0001, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0044, Los Angeles, California, United States
🇺🇸
Local Institution - 0140, Houston, Texas, United States

and more 81 locations

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Phase 1

Completed

Conditions: Liver Dysfunction
Liver Insufficiency
Hepatic Failure
Myocardial Failure
Heart Decompensation
Cardiac Failure
Congestive Heart Failure

Interventions: Drug: BMS-986231

First Posted Date: 2018-05-04

Last Posted Date: 2020-08-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT03515980

Locations: 🇵🇱
KO-MED Centra Kliniczne Lublin, Lublin, Poland
🇭🇺
Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest, Hungary
🇵🇱
BioVirtus Centrum Medyczne, Jozefow, Poland

and more 1 locations

A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)

Conditions: Heart Failure

First Posted Date: 2018-05-03

Last Posted Date: 2018-06-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 99209

Registration Number: NCT03515655

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

Phase 1

Completed

Conditions: Healthy Volunteers

First Posted Date: 2018-04-26

Last Posted Date: 2020-01-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 94

Registration Number: NCT03509883

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Completed

Conditions: Chronic Myeloid Leukemia in Chronic Phase
Philadelphia Chromosome
Chronic Myeloid Leukemia

Interventions: Other: Non-Interventional

First Posted Date: 2018-04-26

Last Posted Date: 2022-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 463

Registration Number: NCT03509896

Locations: 🇨🇳
Local Institution, Tianjin, Tianjin, China

Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

Withdrawn

Conditions: Non-valvular Atrial Fibrillation

Interventions: Other: Non-Interventional

First Posted Date: 2018-04-25

Last Posted Date: 2022-06-30

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03508258

Locations: 🇺🇸
Local Institution, Bethesda, Maryland, United States

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

Completed

Conditions: Atrial Fibrillation
Heart Failure

Interventions: Other: Non-Interventional

First Posted Date: 2018-04-25

Last Posted Date: 2019-01-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60000

Registration Number: NCT03508271

Locations: 🇺🇸
Local Institution, Ann Arbor, Michigan, United States

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Completed

Conditions: Non-small Cell Lung Cancer NSCLC
Small Cell Lung Cancer SCLC
Lung Cancer

First Posted Date: 2018-04-23

Last Posted Date: 2021-09-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6205

Registration Number: NCT03505515

Locations: 🇨🇳
Local Institution, Shanghai, SHG, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy